Information obtained from ClinicalTrials.gov on September 02, 2010
Link to the current ClinicalTrials.gov record.

Size Progression of Macular Degeneration After Cataract Surgery

Status: Completed

Verified by: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery, July 2010

Last Updated: July 19, 2010

Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Collabortator(s): Medizinisch-wissenschaftlicher Fonds des Bürgermeisters der Stadt Wien, that is, Scientific Fund of the Major of the City of Vienna

Purpose

The purpose of this study was to find out if in patients with non-exudative age-related macular degeneration (AMD), randomly assigned to cataract surgery, any AMD size progression or progression to exudative AMD could be detected 6 months after surgery.

Condition: Age-Related Macular Degeneration
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Intervention: Procedure: Cataract Surgery
Phase: Phase 4

Primary Outcome Measures:

• AMD size (defined central region of interest)

Secondary Outcome Measures:

• Functional ophthalmic assessments

Estimated Enrollment: 54
Start Date: January 2002
Primary Completion Date: September 2007

Eligibility

Minimum Age: 18 Years
Maximium Age: N/A
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Gender: Both

Criteria

Inclusion Criteria: - Patients with cataract and non-exudative age-related macular degeneration Exclusion Criteria: - Patients with retinal pathologies other than AMD, exudative AMD, progressive glaucoma, myopia > 10 diopters, panretinal laser treatment, former cataract or vitreoretinal surgery, were excluded.

Location and Contacts

The Rudolph Foundation Hospital, Dept. of Ophthalmology
Vienna,
1030
Austria